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Background: Anemia secondary to iron deficiency is common in patients with non-dialysis dependent chronic
kidney disease (ND-CKD) but it is unclear if oral supplementation is as effective as intravenous (IV) supplementation
in re-establishing iron stores. The purpose of this study was to determine if oral Heme Iron Polypeptide (HIP) is as
effective as IV iron sucrose in the treatment of iron-deficiency anemia for patients with ND-CKD.
Methods: Forty ND-CKD patients were randomized; 18 to HIP 11 mg orally 3 times per day and 22 to IV iron
sucrose 200 mg monthly for 6 months. Baseline clinical and laboratory data were collected for all patients. The
primary and secondary outcomes for the study were hemoglobin (Hgb) concentration and iron indices [ferritin and
percentage transferrin saturation (TSAT)] at the end of 6 months respectively. Adverse events were also compared.
Results: The baseline demographic characteristics and laboratory values were similar for the two groups. After
6 months of treatment, Hb in the HIP group was 117 g/L and 113 g/L in the IV sucrose group (p = 0.37). The TSAT
at 6 months was not different between the two groups {p = 0.82}but the serum ferritin was significantly higher in
the IV iron sucrose group {85.5 ug/L in HIP and 244 ug/L; p = 0.004}. Overall adverse events were not different
between the groups.
Conclusion: HIP is similar in efficacy to IV iron sucrose in maintaining hemoglobin in ND-CKD patients with no
differences in adverse events over 6 months. It is unclear if the greater ferritin values in the IV iron sucrose group
are clinically significant.
Trial registration: ClinicalTrials.gov: NCT00318812
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Anemia develops early during chronic kidney disease
(CKD) and is associated with increased cardiovascular
morbidity, mortality and decreased quality of life [1-3].
Iron deficiency is common in patients with CKD which
limits the effectiveness of erythropoiesis-stimulating
agents (ESA) [4-7]. The estimated prevalence of iron de-
ficiency ranges from 25 to 70% [8,9]. Importantly iron
has many other physiologic functions that may be im-
portant for overall health such as immune function,* Correspondence: dzimmerman@toh.on.ca
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reproduction in any medium, provided the orthermoregulatory performance, energy metabolism, and
exercise or work performance [10].
To replete iron stores, iron can be administered ei-
ther orally or intravenously (IV). Although oral iron is
less expensive, easier to administer, and may be safer,
IV iron enables the administration of larger doses of
iron and is better tolerated by some patients [11]. The
main adverse reactions to oral iron are gastrointestinal
and may limit adherence and dose [12]. The most
feared adverse reaction to IV iron is anaphylaxis, which
is more common with iron dextran than with other
preparations [13,14]. In addition, there are concerns
that IV iron may accelerate kidney damage in patients
with CKD not on dialysis therapy, promote infections
by supplying iron to pathogenic bacteria, enhanceal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Nagaraju et al. BMC Nephrology 2013, 14:64 Page 2 of 7
http://www.biomedcentral.com/1471-2369/14/64atherosclerosis by generating oxidative stress, and cause
endothelial damage [15-18].
In hemodialysis patients several different studies, in-
cluding a randomized controlled trial, have consistently
demonstrated that intravenous iron supplementation is
superior to oral iron replacement with respect to enhan-
cing body iron stores, augmenting hemoglobin levels
and reducing ESA requirements [19-21]. Among pa-
tients with ND-CKD, by contrast, evidence for an opti-
mal iron replacement strategy, safety, and test utility is
less clear. There is controversy about when to start iron
supplementation, target values for ferritin and TSAT
such that the 2008 Canadian Society of Nephrology
guidelines for management of iron deficiency anemia are
Grade D [22]. There is also ongoing controversy as to
whether iron supplementation is best administered orally
or intravenously in ND-CKD and peritoneal dialysis pa-
tients [23]. There are only a few comparative studies be-
tween IV iron infusion and oral iron supplementation
and the conclusions are conflicting [24-28].
Heme iron polypeptide (HIP) is a new generation oral
iron which uses the heme porphyrin ring to supply iron
to sites of absorption in the intestinal lumen. In com-
parison with the other standard iron preparations, pre-
liminary evidence suggests that HIP may represent a
promising new strategy for oral iron replacement
[29-31]. For this reason, we performed a randomized
controlled trial to determine if oral HIP is as effective
as IV iron sucrose in the treatment of iron-deficiency
anemia for patients with ND-CKD.
Methods
Study design
This was a single blind (investigator), randomized con-
trolled trial performed at the Ottawa hospital from May
2007 to February 2011(NCT00318812). Randomization
was via a computer generated sequence; group allocation
was stored in sealed opaque sequentially numbered en-
velopes. The study protocol and all amendments were
approved by the Ottawa Hospital Research Ethics Board.
The original protocol was to include patients with an
eGFR < 30 mls/minute and Hgb of 90–110 but was modi-
fied secondary to recruitment challenges. All ND-CKD
patients > 18 years old with an estimated glomerular fil-
tration rate (eGFR) ≤60 ml/min/1.73 m2 with anemia
[90–120 g/L (females) 90–135 g/L (males)] and iron indi-
ces lower than the CSN recommended targets (serum
ferritin < 100 ucg/L or TSAT < 20%) were invited to par-
ticipate. Patients were excluded if they had received par-
enteral iron therapy or blood transfusion within the last
3 months, were pregnant, or had a history of recent ma-
lignancy, infection, GI bleed or major surgery. If the pa-
tient was already on an oral iron preparation, the
preparation was stopped and the patient was included inthe study after a wash out period of two weeks. Patients
were also excluded if serum folate or vitamin B12 levels
were below the normal limits (< 15 nmol/L, <133 pmol/L
respectively). If the participant was being treated with
an ESA, the medication was continued and the dose
was adjusted by the blinded study investigator to main-
tain Hgb from 100-120 g/L. If the participant was not
on an ESA at study entry, once the participant was iron
replete (TSAT 20-50% and ferritin 100-500 ucg/L), if
the Hb was <100 g/L, an ESA was started.
Measurements
Laboratory tests were done at the Ottawa Hospital.
Hemoglobin was measured from plasma using spectro-
photometric scan with a coefficient of variation of 4%.
Ferritin was measured with an automated immunoassay
with a CV of 5%. Iron and transferrin were measured
with the ferrozine method with a CV of 3% and immu-
nonephelometry with a CV of 5% respectively.
Treatment and follow up
After providing informed consent, patients were ran-
domized to receive IV iron sucrose 200 mg monthly or
HIP 11 mg orally three times a day for total of 6 months.
Absorption of HIP in chronic kidney disease is approxi-
mately 18.6% such that 33 mg per day is roughly equiva-
lent to 200 mg IV iron sucrose [32].
Baseline clinical data and laboratory investigations
were collected as per the protocol at the time of enroll-
ment. Patients were followed monthly for compliance
(pill counts) and possible adverse effects (standardized
questionnaire) in both groups. The questionnaire spe-
cifically asked patients to quantify (none, somewhat/
occasionally, a lot/often) if they experienced constipa-
tion (<1 bowel movement per 2 days), diarrhea (> 3
bowel movements per day), bloating, nausea, cramps,
indigestion, muscle cramps, episodes of low blood pres-
sure and skin rash at 2, 4 and 6 months. Hemoglobin
was repeated monthly and iron indices were repeated
every two months.
Premature withdrawal was defined as initiation of
renal replacement therapy, blood transfusion, non-
adherence (refusal to take study medication) or with-
drawal of consent.
Outcome
Summary descriptive statistics were calculated to de-
scribe the study patient population using SAS enterprise
(version 4.2). Results are expressed as median and inter-
quartile range for continuous data and percentage and
frequency for categorical data. The primary outcome
was a comparison of Hb concentration at 6 months be-
tween the two groups using the Wilcoxon two –sample
test. A similar analysis was done for the secondary
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analysis was utilized. Where there was missing data, the
last value was carried forward for any patients with a pre-
mature withdrawal from the study protocol for whatever
reason. We also examined the requirement for erythro-
poietin and adverse events with the medication.
Results
Between May 2007 to February 2011, 55 patients were
consented to participate in the study and 40 patients
were randomized to the treatment groups (Figure 1).
There were 22 patients in the IV iron sucrose group and
18 patients in the oral HIP group. Demographics and
baseline characteristics of the study population were
similar in the two groups as shown in Table 1.
The baseline hemoglobin was 110.5 g/L {inter quartile
range (IQR): 104–119} in the HIP group and 108.5 g/L
(IQR:102–117) in the IV iron sucrose group. The baseline
serum ferritin was 71 ug/L (IQR: 40–143) in HIP group
and 67 ug/L (IQR: 27–100) in IV iron sucrose group. Base-
line serum TSAT was 17% (IQR14-20) in HIP group and
16.5% (IQR 10–20) in IV iron sucrose group. The eGFR
was comparable between both groups {20.5 ml/min/
1.73 m2 (IQR:12–26) in HIP and 23 ml/min/1.73 m2
(IQR:18–33) in IV iron sucrose group}. Similar num-
bers of patients who were already on ESA treatment.




Hgb too high – 6
Hgb too low – 1
B12 / folate too low – 5
eGFR too high – 1
TSAT & ferritn too high – 1 
Enrolled in 2 research studies - 1
Hgb too high 477
% sat/ ferritin too high 267
On venofer – 128
eGFR too high/low – 35
B12/folate too low 23
Other - 26
Not interested – 209
Figure 1 Trial flow.study as per protocol in the HIP group and 19 of 22
(86%) in the IV iron sucrose group.
After 6 months of treatment there were increases
in the Hb, TSAT and serum ferritin in both the
groups compared to their baseline values (Table 2).
There was no difference in the Hb in the HIP group
was 117 g/L and 113 g/L in the IV sucrose group at
6 months (p = 0.37; Table 3). Among iron indices, the
TSAT at 6 months was also similar in both the
groups {21.5%(17–29) in HIP and 21.5% (17–27) in
IV sucrose; p = 0.82}, whereas serum ferritin was sig-
nificantly higher in the IV iron sucrose group com-
pared to HIP group {85.5 ug/L (44–104) in HIP and
244 ug/L (71.5-298); p = 0.004}. In the oral HIP group,
in addition to the 6 patients who were on an ESA at
study entry, one more patient was started on ESA by
study completion. In the IV iron sucrose group, one of
the 6 patients was able to discontinue ESA therapy.
Three patients in IV iron sucrose and 4 patients in
oral HIP group withdrew from the study. In the IV iron
sucrose group one patient was non adherent to the study
protocol, one patient required blood transfusion and one
had surgery requiring withdraw from the study. In HIP
group, one patient was non adherent and 3 patients
discontinued secondary to new or worsening abdominal
cramps. Overall adverse effects are similar between both






IV Iron Sucrose – 22
19 Completed
Table 1 Baseline characteristics of both groups (median/interquartile range)
Parameter HIP IV sucrose p-value
Number of patients (Randomized) 18 22
Age(years) 76 (66–83) 66 (58–76) 0.10
Sex Male −13 Female −5 Male −12 Female −10 0.33
Race Caucasians −16 Africans −1 Others −1 Caucasians- 15 Africans-6 Others-1 0.12
Blood pressure (mm Hg) Systolic 130 (122–140) 131 (124–140) 0.85
Blood pressure (mm Hg) Diastolic 67 (62–75) 68 (60–72) 0.76
Hemoglobin(g/L) 110.5 (104–119) 108.5 (102–117) 0.39
Serum ferritin(ug/L) 71 (40–143) 67 (27–100) 0.59
TSAT 17 (14–20) 16.5 (10–20) 0.37
Patients on ESA* 7 6 1.0
Average ESA dose (ug/month) 60(60–80) 80(60–100) 0.20
Serum creatinine(umol/L) 246.5 (206–362) 216.5 (176–351) 0.48
Glomerular filtration rate
(ml/min/1.73 m2)
20.5 (12–26) 23 (18–33) 0.39
Serum albumin 38 (35–39) 38.5 (36–41) 0.58
Intact PTH 13.05 (6.1-20.1) 13.3 (7.9-16.75) 0.93
Serum phosphate 1.28 (1.07-1.42) 1.28 (1–1.54) 0.96
Cause Of ESRD Diabetes – 6 Ischemic nephropathy-3
Hypertension – 3 Unknown – 3 Others – 3
Diabetes −9 Ischemic nephropathy-6 Hypertension – 1
Unknown – 5 Others – 1
0.22
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were the most common adverse effects in both groups with
constipation and abdominal cramps being the most com-
mon in HIP group and constipation in IV sucrose group.
Symptomatic hypotension occurred in 3 patients in the IV
iron sucrose group during infusion (13%).
Discussion
In our single blinded study comparing 11 mg 3 times
per day oral HIP to 200 mg IV iron sucrose monthly, we
did not find any difference in Hb after 6 months of ther-
apy. The TSAT improved in both groups and was not
statistically different between the patients treated with
HIP or IV iron sucrose. However, the ferritin increased
more in the IV iron sucrose group and this was statistically
significant. Adverse events were similar in both groups.
Anemia develops early during CKD and is associated
with increased cardiovascular morbidity, mortality andTable 2 Change in Hgb, ferrtin and TSAT from baseline to 6 m
Parameter HIP baseline HIP 6 m p-value
Hgb 110.5 117 0.15
(104–119) (110–128.8)
Ferritin 71 85.5 0.81
(40–143) (44–104)
TSAT 17 21.5 0.05
(14–20) (17–29)decreased quality of life for CKD patients [1-3]. As CKD
progresses, Hgb falls because of a decrease in erythro-
poietin production as well as iron deficiency that de-
velops secondary to decreased absorption and increased
loss. Although iron stores can be restored with either
intravenous or oral iron, both therapies have potential
risks and benefits. Intravenous iron may be convenient
for some patients (especially those on hemodialysis) and
may be associated with less gastrointestinal side effects
[11,12]. However, intravenous iron is expensive and may
be associated with hypotension, serum sickness type re-
actions and anaphylaxis [13,14]. Oral iron may be more
convenient for ND-CKD and peritoneal dialysis patients,
but data on the efficacy of oral iron is conflicting.
HIP is produced by hydrolysis of bovine hemoglobin
resulting in a highly soluble heme moiety that contains
more than 1% iron. Since heme is absorbed via a differ-
ent receptor than non heme (ionic) iron, the absorptiononths by treatment group







Table 3 Primary and secondary outcomes: hemoglobin,
serum ferritin, TSAT and ESA requirement at 6 month
Parameter HIP IV sucrose p-value
Hgb (g/L) 117 (110–128.8) 113 (107.5-120.3) 0.37
Serum ferritin (ug/L) 85.5 (44–104) 244 (71.5-298) 0.004
TSAT (%) 21.5 (17–29) 21.5 (17–27) 0.82
Average ESA dose at
6 month (ug/month)
60 (7 patients) 50 (5 patients) 0.56
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and ionic iron are dissimilar [29,30]. Administration of
HIP to 14 healthy subjects was associated with fewer
side effects and significantly higher bioavailability com-
pared with nonheme iron [31]. HIP increased serum iron
levels 23 times greater than ferrous fumarate on a
milligram-per- milligram basis [31]. Hallberg et al. has
also shown enhanced absorption of heme iron compared
to iron salts even in subjects with serum ferritin levels
greater than 400 ng/mL (898 pmol/L) [33].
Although we did not compare HIP to another non-
heme iron, we were able to show that supplementation
of HIP to patients with ND-CKD was able to maintain
Hb and improve measures of iron indices over a 6 month
period. The gastrointestinal adverse events were not
greater in the HIP group than the IV iron sucrose group.
Our study results are consistent with a study published
by Nissenson et al. on hemodialysis patients [34]. They
performed an open-label, pre-test/post-test trial of HIP
(1 tablet tid) administered instead of intravenous iron to
37 ESA-treated hemodialysis patients over a 6 month
period. Although in their study 25% of patients dropped
out or were excluded, oral HIP was able to successfully
replace IV iron therapy in the majority of patients on
hemodialysis. Hematocrit targets and iron stores were
maintained and a significant improvement in ESA effi-
ciency (p = 0.04) was reported. However, the results ofTable 4 Adverse events
Parameter HIP (18) IV sucrose (22)
> 1 Adverse event 4 4
Constipation 5 4
Diarrhoea 2 3
Bloating sensation 3 2
Abd cramps 5 3
Nausea 2 2
Dyspepsia 1 3
Muscle cramps 5 2
Symptomatic hypotension 0 3
Skin rash 1 0
Overall 28 26Nissenson et al. study were limited by the study design,
high drop-out rate (25% over 6 months) and failure to
analyze on an intention to treat basis [34].
In ND-CKD anemia studies, 7 randomized controlled
trials comparing the efficacy of IV iron to oral iron
have been reported and yielded contradictory results
[24-28,35,36]. The studies differed in several important
ways including baseline Hb levels, study duration, iron
status of the patients, sample size and type of IV iron
preparations. In the meta-analysis by Rozen-Zvi et al.,
there was a small improvement in Hb concentration in
patients treated with IV iron compared to oral iron
[0.31 g/dl (0.09 to 0.53)], the clinical significance of
this small difference is questionable [37].
In our study HIP, was compared with IV iron sucrose
at doses that were considered roughly equivalent over
6 month duration. Under these conditions, HIP appeared
to have similar efficacy in maintaining hemoglobin with
no increase in gastrointestinal side effects. However,
similar to previous randomized studies, the serum fer-
ritin was significantly higher in IV iron group, in spite of
similar TSATs in the HIP group. A similar result was
seen in the recently completed HEMATOCRIT trial in
which the serum ferritin was also higher in peritoneal
dialysis patients treated with ferrous sulfate compared to
HIP [38]. It is unclear if the increased ferritin is clinically
significant. However, the ability to withdraw the ESA in
one patient in the IV iron sucrose group but not in the
HIP iron group requires further study.
There are several limitations to our study. We had
limited ability to detect a difference in Hgb values due
to our small sample size (power 0.56). In designing a
non-inferiority trial of HIP versus IV iron sucrose with a
difference of 2 g/L in the mean of the Hb values would
require 694 patients. The difficulties with recruitment
and the lack of interest in participation in the study sug-
gest that a repeat study aiming for a larger ‘N’ would not
be feasible at our centre. We also did not examine the
potential effects on oxidative stress between the two
different types of iron and the effect of iron prepara-
tions on eGFR [14]. Since the maximum follow up has
been 6 months in all the studies including our study, it
limits our ability to draw conclusions regarding the long
term consequences of different treatment regimens on
Hb levels, progression of CKD (eGFR) and clinical out-
comes, such as mortality, cardiovascular outcomes, and
quality of life. Long term follow-up is especially import-
ant given the concerns about oxidative stress, infection
risk, and cardiovascular morbidity and mortality second-
ary to the free iron released into the circulation from the
IV preparation [12,15-18]. The ongoing randomized
study by Agarwal et al., in which the effect of oral versus
IV iron on GFR and proteinuria will be assessed over a
2 year period may address a couple of the issues [39].
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In conclusion, we have shown in this single blinded
randomized controlled trial that HIP was as effective
in maintaining Hb concentration in ND-CKD pa-
tients as IV iron sucrose over a 6 month period. The
results of the ongoing randomized studies with lon-
ger follow up are required to answer the important
questions related to morbidity and mortality. Further
studies are also required to determine the optimal
time to intervene with iron therapy since iron also
has other physiologic functions.
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